Lenalidomide
Lenalidomide is an immunomodulatory antineoplastic agent used primarily in hematologic malignancies.
Lenalidomide is an immunomodulatory antineoplastic agent used primarily in hematologic malignancies. It is a thalidomide analog and is best known for its ability to modulate the tumor microenvironment, enhance immune effector function, and exert direct anti-myeloma and anti-lymphoma activity. A key molecular feature of lenalidomide is its interaction with cereblon, the substrate receptor component of the CRL4 E3 ubiquitin ligase complex, which underlies many of its downstream biological effects and has also made lenalidomide a widely used chemical tool in targeted protein degradation research.
Clinically, lenalidomide is an established backbone therapy in multiple myeloma and several B-cell lymphomas, often combined with dexamethasone, rituximab, bortezomib, daratumumab, carfilzomib, tafasitamab, or other agents. Its use in combination regimens reflects both its immunostimulatory properties and its synergy with monoclonal antibodies and other anti-cancer drugs. In recent research, lenalidomide has also been explored in T-cell lymphoma and in mechanistic studies involving cereblon-binding and PROTAC design.
Where the papers sit
14 papers from the last 6 months study lenalidomide directly · updated from PubMed 5 Nov 2026
Study type 6 clinical trials · 4 observational · 1 human data · 2 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
Newly Diagnosed Myeloma Combinations
Frontline multiple myeloma treatment is consolidating around multi-agent regimens built on bortezomib, lenalidomide and dexamethasone, increasingly with daratumumab. Trials emphasize progression-free survival and minimal residual disease in transplant-eligible and transplant-ineligible patients, while selinexor targets high-risk disease. Longitudinal M-MDSC expansion is being evaluated as a marker of response. Retrospective safety analyses and warnings about premature interim conclusions temper comparisons across regimens.
6 papers · 42.9%
-
Multiple Myeloma Therapy
Treatment is moving beyond conventional lenalidomide use toward molecularly targeted strategies and more individualized maintenance in multiple myeloma. A GLUT-directed molecular glue is being developed for IMiD-resistant disease, while studies compare continuous with fixed-duration maintenance. Dosage simulations address demographic and ethnic differences rather than assuming one regimen fits all. Retinal artery occlusion reported with abemaciclib and lenalidomide keeps rare vascular toxicity under scrutiny.
4 papers · 28.6%
-
Lymphoma Immunotherapy Combinations
Lenalidomide is being paired with antibody-based therapy rather than used in isolation for B-cell lymphoma. Epcoritamab plus rituximab and lenalidomide is being tested in first-line and relapsed or refractory follicular lymphoma, while tafasitamab-lenalidomide is added to R-CHOP for high-risk DLBCL. Comparisons with usual care focus on clinical benefit and treatment positioning. Radiolabeled lenalidomide complexes remain a separate preclinical extension toward imaging and targeted delivery.
4 papers · 28.6%
Lenalidomide is repurposed as a directly radiolabeled bioorganometallic imaging and drug-development platform
The rhenium- and technetium-99m–lenalidomide sandwich-complex study treated lenalidomide not primarily as a therapeutic cereblon-binding immunomodulatory agent, as in the other papers, but as a ligand for chelator-free radiolabeling and metallodrug development. It produced aqueous [99mTc(η6-lena)2]+, characterized a rhenium analogue, and demonstrated rapid blood clearance with predominant renal excretion in mice; the complexes retained measurable but substantially weaker cereblon binding than lenalidomide itself. This extends lenalidomide into pharmacokinetic imaging and bioorganometallic probe design, rather than another therapeutic regimen or treatment-response study 42627009Aug.
Papers
The 14 papers from the last 6 months that study lenalidomide directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Newly Diagnosed Myeloma Combinations (6)
- Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study. Trials · 28 Aug 2026 PMID 42661196
- Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. Annals of medicine · 3 Aug 2026 PMID 42544613
- Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
- Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. Clinical and translational science · 30 Jun 2026 PMID 42374568
- Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
- The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749
Multiple Myeloma Therapy (4)
- Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association. BMJ case reports · 28 Sept 2026 PMID 42805625
- Discovery of molecular glue degrader for treatment of IMiDs-resistant multiple myeloma based on GLUT-mediated tumor targeting strategy. Bioorganic chemistry · 6 Aug 2026 PMID 42561560
- A Simulation-Based Assessment of Dosage Regimen Appropriateness for Multiple Myeloma Medicines Reflecting Demographic and Ethnic Differences. Clinical and translational science · 28 Jul 2026 PMID 42515832
- Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. The New England journal of medicine · 15 Jul 2026 PMID 42456135
Lymphoma Immunotherapy Combinations (4)
- Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. The Lancet. Haematology · 27 Aug 2026 PMID 42660129
- Chelator Free Radiolabeling and Preclinical Evaluation of η6-Arene Sandwich Complexes of Lenalidomide With Rhenium and Technetium-99m. Chembiochem : a European journal of chemical biology · 21 Aug 2026 PMID 42627009
- Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. Oncoimmunology · 8 Jul 2026 PMID 42415230
- Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England) · 30 May 2026 PMID 42217458
By study type
Clinical trials (6)
- Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study. Trials · 28 Aug 2026 PMID 42661196
- Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. The Lancet. Haematology · 27 Aug 2026 PMID 42660129
- Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. The New England journal of medicine · 15 Jul 2026 PMID 42456135
- Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. Oncoimmunology · 8 Jul 2026 PMID 42415230
- Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood advances · 3 Jun 2026 PMID 42234958
- Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England) · 30 May 2026 PMID 42217458
Observational studies and case reports (4)
- Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association. BMJ case reports · 28 Sept 2026 PMID 42805625
- Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. Annals of medicine · 3 Aug 2026 PMID 42544613
- Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
- Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. Clinical and translational science · 30 Jun 2026 PMID 42374568
Human data, design not indexed (1)
- A Simulation-Based Assessment of Dosage Regimen Appropriateness for Multiple Myeloma Medicines Reflecting Demographic and Ethnic Differences. Clinical and translational science · 28 Jul 2026 PMID 42515832
Preclinical: animal, cell and lab studies (2)
- Chelator Free Radiolabeling and Preclinical Evaluation of η6-Arene Sandwich Complexes of Lenalidomide With Rhenium and Technetium-99m. Chembiochem : a European journal of chemical biology · 21 Aug 2026 PMID 42627009
- Discovery of molecular glue degrader for treatment of IMiDs-resistant multiple myeloma based on GLUT-mediated tumor targeting strategy. Bioorganic chemistry · 6 Aug 2026 PMID 42561560
Unclassified: not yet indexed with MeSH (1)
- The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology · 22 May 2026 PMID 42171749
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-28. Last written: 2026-08-30 by GPT. Drafted by language models from published abstracts; not medical advice.